Transcript Slide 1

Academic & Community Cancer
Research United (ACCRU)
Scientific Achievements
Completed ACCRU Studies
2006-2011*
• Number of studies: 29
• Tumor types:
•
•
•
•
•
•
•
•
•
Breast – 8
Cancer control - 5
CRC – 4
Ovarian – 3
Lung – 3
Lymphoma – 2
Melanoma – 2
Gastroesoph – 1
Pancreas – 1
Studies
Breast
CRC
Ovarian
Lung
Lymphoma
Melanoma
Gastroesoph
Pancreas
Cancer control
*Includes research conducted by Mayo Clinic Cancer Research Consortium (MCCRC)
Accrual
• Total accrual: 1698 patients
• Tumor types:
•
•
•
•
•
•
•
•
•
Cancer control - 943
CRC – 295
Breast – 202
Lymphoma – 72
Lung – 71
Ovarian – 39
Gastroesoph – 33
Pancreas – 27
Melanoma – 15
Highlights
Breast cancer
Study design
Results
AVF3694g
A Multicenter, Phase III,
Randomized, Placebo-Controlled
Trial Evaluating the Efficacy and
Safety of Bevacizumab in
Combination with Chemotherapy
Regimens in Subjects with
Previously Untreated Metastatic
Breast Cancer (RIBBON I)
Robert et al., JCO 2011
AVF3693g
AVF3693g A Phase III,
Multicenter, Randomized,
Placebo-Controlled Trial
Evaluating the Efficacy and
Safety of Bevacizumab in
Combination with Chemotherapy
Regimens in Subjects with
Previously Treated Metastatic
Breast Cancer (RIBBON II)
Brufsky et al., JCO 2011
Highlights
Breast cancer
Study design
Results
RC0639
Phase II Study of Cardiac Safety
and Tolerability of an Adjuvant
Chemotherapy plus Trastuzumab
with Lapatinib in Patients with
Resected HER2+ Breast Cancer
Palmieri et al., AACR
2009
Johnson et al., AACR
2009
Highlights
Colorectal cancer
Study design
Results
14387
(CORRECT)
A Randomized, Double-Blind,
Placebo-Controlled Phase III
Study of Regorafenib Plus BSC
Versus Placebo Plus Best
Supportive Care in Patients with
Metastatic Colorectal Cancer
(CRC) Who Have Progressed
After Standard Therapy
Grothey et al., Lancet 2012
L_9444
(CONcePT)
A Phase IV, Randomized,
Prospective, Multicenter
Comparison of an Intermittent
Schedule of Oxaliplatin (IO)
Combined with 5-Fluorouracil,
Leucovorin (FOLFOX)
Bevacizumab versus the
Conventional (CO) Mode of
Administration of
FOLFOX/Bevacizumab Plus
Neuro-prophylaxis with
Calcium/Magnesium for the
Optimization of First-Line Therapy
of Metastatic Colorectal Cancer
Grothey et al., ASCO 2008
Manuscript submitted as
Hochster et al.
Highlights
Colorectal cancer
Study design
Results
RC0948
The Oncotype DX Colon Cancer
Assay for Stage II Colon
Carcinoma: does it impact on
physician adjuvant treatment
decision making and patient
satisfaction?
Data to be presented at
ASCO GI Symposium 2013
Alberts et al.
Highlights
Ovarian cancer
Study design
Results
B9E-US-S302
Phase III Randomized Trial of
Induction Chemotherapy with
Gemcitabine and Carboplatin
Followed by Elective Paclitaxel
Consolidation versus Paclitaxel
and Carboplatin Followed by
Elective Paclitaxel Consolidation
in Patients with Primary Epithelial
Ovarian, Primary Peritoneal
Cancer or Fallopian Tube
Carcinoma
Gordon et al., Gynecol
Oncol 2011
RC0661
LAPTOP-OC: A Phase II Trial of
Lapatinib in Combination with
Weekly Topotecan in Patients
with PlatinumRefractory/Resistant Ovarian and
Primary Peritoneal Carcinoma
Weroha et al., Gynecol
Oncol 2011
Highlights
Melanoma
Study design
Results
AVF4096g (BEAM)
A Phase II, Multicenter,
Randomized, Double-Blind,
Placebo-Controlled Trial
Evaluating the Efficacy and
Safety of Bevacizumab in
Combination With Carboplatin
and Paclitaxel Chemotherapy for
the First-Line Treatment of
Patients with Metastatic
Melanoma
Kim et al., JCO 2012
Highlights
Lymphoma
Study design
Results
MC0485 (ROAD)
A Phase II Trial of Oxaliplatin,
Cytosine Arabinoside,
Dexamethasone with Rituxan
(ROAD) in Patients with
Relapsed CD20+ B-Cell NonHodgkin's Lymphoma
Johnston et al., ASCO 2009
Highlights
Cancer control
Study design
Results
MC04CC
Phase III, randomized study of
the effects of
parenteral iron, oral iron, or no
iron supplementation on the
erythropoietic response to
darbepoetin alfa for patients with
chemotherapy-associated
anemia.
Blood 2009 Nov 20;
114(22):261;
Zoledronic acid for treatment of
osteopenia and osteoporosis
in women with primary breast
cancer undergoing adjuvant
aromatase inhibitor therapy.
Breast. 2010 Apr; 19(2):926.
MC05C8
J Clin Oncol. 2011
Jan 1; 29(1):97-105.
Contact Information
• Dr. Axel Grothey, Professor of Oncology
• ACCRU Chair
• [email protected]
• 507-284-5352
• Ms. Aimee Tillman,
• ACCRU Program Manager-Operations
• [email protected]
• 507-266-4636
• Main Research Coordinating Center
• [email protected]
• 507-538-7448
©2011 MFMER | slide-12